TRDA Earnings — Entrada Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
TRDA — Entrada Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$7.07
Market Cap$274.5M
P/E—
52W Range$4.93 – $16.45
Next Earnings2026-08-05
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
